According to the World Health Organization, about 1 in 8 people suffer from a mental health disorder, and while access to care is improving, over 75% of people with mental, neurological, and substance use disorders still cannot access the treatment or care they need*. This World Mental Health Day, we are proud to support companies at the forefront of mental healthcare innovation, dedicating their efforts to delivering the best possible care and helping people live healthier and happier lives. This year's theme, 'mental health in the workplace', reminds us of the critical importance of mental health in all settings of our lives. Eleos Health leverages cutting-edge AI to assist clinicians in delivering more personalized care. By automating documentation and offering detailed clinical insights, Eleos empowers providers to spend more time focusing on patient care. Better Life Partners delivers comprehensive support for those dealing with substance use disorders, combining medical and behavioral health services. Through a multidisciplinary, team-based approach, they help individuals on their recovery journeys with compassionate, holistic care. Together, these companies are paving the way for high-quality, accessible mental health care. We are honored to partner with innovators who are driving healthcare forward and making a difference in people's lives. #WorldMentalHealthDay #MentalHealthAtWork #InnovationInHealthcare #aMoonFund #AcceleratingCure Yair Schindel, MD, MBA | Gaby Hirsch | Roy Wiesner | Alon Joffe | Juliana Ekong *WHO: https://lnkd.in/eEZdadwz
aMoon Fund
Venture Capital and Private Equity Principals
Ra'anana עוקבים, Israel 9,350
Accelerating Cure
עלינו
aMoon is a global HealthTech and Life Sciences investment fund based in Israel. As Israel’s largest HealthTech fund, with $1.1 billion AUM, we partner with outstanding entrepreneurs who harness groundbreaking science and technology to transform healthcare. Together with our portfolio companies, we work tirelessly to advance solutions that will help people live healthier, better lives. We harness our unique team of over 50 scientists, physicians and entrepreneurs and our global network of investors and industry leaders to build bridges between our portfolio companies and global tech, finance and medical research hubs to help entrepreneurs turn their vision into reality. Through our Velocity Fund we invest in companies pursuing disruptive, cutting-edge technologies as early as venture formation through Series A. Our Growth Fund invests in later-stage companies that are either generating revenue in growth rounds, pre-IPO rounds or in pivotal clinical trials.
- אתר אינטרנט
-
http://amoon.fund/
קישור חיצוני עבור aMoon Fund
- תעשייה
- Venture Capital and Private Equity Principals
- גודל החברה
- 11-50 עובדים
- משרדים ראשיים
- Ra'anana, Israel
- סוג
- שותפות
- הקמה
- 2016
- התמחויות
מיקומים
-
הראשי
34 Jerusalem Road
Ra'anana, Israel 4350108, IL
עובדים ב- aMoon Fund
עדכונים
-
Congratulations to Theranica on the expansion of Medicaid coverage for Nerivio® in Arizona, New Jersey, Ohio, and Virginia! With this latest milestone, an additional 7 million people will have access to Nerivio®, an FDA-cleared wearable device for migraine treatment in adults and adolescents aged 12+. This expansion highlights the growing adoption of non-drug, tech-enabled healthcare solutions, providing an alternative to medications that may not be effective or well-tolerated. At aMoon, we are proud to partner with Theranica as they continue their mission to enhance the quality of life for people with pain disorders. Read more about the expanded coverage in the BioSpace article below. #healthcareinnovation #wearabletech #migrainecare #migraine #migraineawareness #medtech Todd Sone | Yair Schindel, MD, MBA | Tomer Berkovitz |Adam Kotzen | Gaby Hirsch | Alon Ironi https://lnkd.in/ddhGmD-y
-
Today, October 7th, marks one year since the darkest day in modern Israeli history. Today we remember the fallen, the hostages, the wounded, and all those affected by the ongoing terror. May we see our hostages return home soon, and may this year bring lasting peace. #bringthemhome
-
aMoon Fund פרסם מחדש את זה
Dr. Judy Chou, President & CEO of AltruBio Inc. will be presenting at aMoon Fund’s exclusive event, October 8, 2024 in Boston, as one of the industry leaders in the field of Inflammation & Immunology. She will be discussing the novel Immune Checkpoint Enhancer (ICE) mechanism which has been clinically validated by AltruBio and the PSGL-1 agonist antibody, ALTB-268, currently being evaluated in two Phase 2 studies for the treatment of moderately to severely active Ulcerative Colitis.
-
Shana Tova from aMoon! Wishing all of our partners, entrepreneurs, friends, and family a happy and sweet new year. May the coming year be filled with peace, health and happiness. 🍎🍯 #ShanaTova #HappyNewYear #HealthTech #aMoonFund Yair Schindel, MD, MBA | Reut Shema | Tomer Berkovitz | Yael Gruenbaum-Cohen | Yaron Daniely | Roy Wiesner | Todd Sone | Osnat Hakimi | Adam Kotzen | Osnat Tirosh | Gaby Hirsch | Vered Gigi, PhD | Ahuvit David
-
We are excited to support Air Doctor with their efforts to ensure people have access to excellent medical care, in a timely manner, wherever they are in the world. Yair Schindel, MD, MBA Tomer Berkovitz Todd Sone Adam Kotzen Tamir Maixner Osnat Hakimi #aMoonFund #HealthTech #Innovation
Exciting News from Air Doctor - we've secured $20M in Series B funding! 👏👏👏 Led by aMoon Fund and supported by key industry players like Tokio Marine Group, Samsung Ventures (SVIC), and current shareholders Lightspeed Venture Partners, Vintage Investment Partners, Phoenix Insurance, and Munich Re Ventures. This investment accelerates our global expansion, enhancing our ability to offer seamless healthcare experiences for travelers across 84 countries (and counting). Above all, it solidifies our position as a leader in travel healthcare. We're proud of how far we’ve come, and we’re excited for what’s next. Together, we're setting a new market standard in global healthcare access. 🌍 Read it here: https://lnkd.in/eZFE7V2c #GlobalExpansion #InsurancePartners #B2B #SeriesB #TravelHealthcare #Insurance #InsurTech #Innovation
-
aMoon Fund פרסם מחדש את זה
So exciting!
For the Hebrew New Year, here is an exciting open position ! Coltac Therapeutics, a stealth-mode VC-backed startup focused on the cutting-edge field of molecular glues, is seeking a highly motivated and skilled Head of Computational Drug Discovery. For the full job description, click here https://lnkd.in/dbjinuPy To apply please send your updated CV to CV@Coltactx.com aMoon Fund, Israel Biotech Fund
-
Today, aMoon has paused to support the families of the hostages and to honor the memory of six hostages who were murdered in captivity; Hersh Goldberg-Polin, Almog Sarusi, Ori Danino, Alexander Lobanov, Carmel Gat and Eden Yerushalmi. May their memories be for a blessing, may their families be comforted and may all those that remain in captivity be returned home soon. #BringThemHomeNow
-
Congratulations to this year's cohort, the third and largest of the Innovation Fellows Program, led by aMoon General Partner, Dr Yaron Daniely. We are thrilled to see the program's evolution over the last three years, and the expansion of aMoon's scientific and professional network in Australia to drive innovation in the ecosystem and accelerate cure. https://lnkd.in/eHjNkgxb Yair Schindel, MD, MBA, Moshe Mor, Yael Gruenbaum-Cohen, Roy Wiesner, Vered Gigi, PhD, Yaniv Sadka, Osnat Hakimi, Ohad Hollander, Tamar Farfel-Becker, PhD
Big thanks to everyone from the #biotech and #research sectors who attended the pitch event at Ovolo South Yarra this week – this was the final workshop of the WEHI-Baker Institute aMoon Innovation Fellows Program. I’m sure you will agree there were some exciting scientific projects and translation pathways showcased. Guest speakers included Dr Yaron Daniely, General Partner and Head at aMoon, a global HealthTech and Life Sciences investment fund based in Israel. Dr Daniely was formerly President and CEO of Yissum, Hebrew University’s Technology Transfer Company, and Co-Chairperson of the Israel Technology Transfer Network. And a special shout out to our host, the Baker Institute’s Executive GM of Commercialisation, Dr Guy Krippner. Hats off to researchers from the Olivia Newton-John Cancer Research Institute, Burnet Institute and the Baker Heart and Diabetes Institute for pitching their innovative projects, and to all the Institutes who had participants take part in the program including Murdoch Children's Research Institute (MCRI), Hudson Institute of Medical Research, St Vincent's Institute of Medical Research and WEHI (Walter and Eliza Hall Institute of Medical Research). This is the third aMoon Innovation Fellows Program which started at the Baker Institute, with the content primarily delivered by aMoon as well as local commercialisation experts. Jumar Bioincubator FB Rice Brandon Capital MTPConnect PAN Group BioCurate Pty Ltd Double Helix Investment Corp Tin Alley Ventures Association of Australian Medical Research Institutes (AAMRI) Newburyport Partners CSIRO Hon. Jaala Pulford Heidi Roache Anna Tran
-
Congratulations to Nectin Therapeutics on announcing their global license agreement with Immunome, Inc.! We've been proud to support the company from day one and are looking forward to what lies ahead. Yaron Daniely Yael Gruenbaum-Cohen Vered Gigi, PhD
Today we are honored to announce a global license agreement with Immunome, Inc. Under the terms of the license, Immunome received exclusive rights to a panel of antibodies targeting a novel undisclosed target. “This agreement allows Nectin Therapeutics to realize value while further pursuing and enabling the focus on our first-in-class anti-PVR program (NTX1088) through its ongoing clinical study in tumor types with high unmet need, in parallel to advancing our novel #ADCs into clinical development. Immunome’s leadership team’s track record of developing and commercializing novel ADC therapies makes it an ideal partner to advance these promising assets,” said Fabian Tenenbaum, Chief Executive Officer of Nectin Therapeutics. “Immunome believes the next generation of transformative antibody-drug conjugates will address novel targets by pairing high-quality antibodies with innovative linker-payload technology,” said Clay Siegall, PhD, President and Chief Executive Officer of Immunome. “We appreciate the work Nectin has done on these antibodies and look forward to advancing them further.” To read about the news: https://lnkd.in/g68U9GBf #CancerResearch #Immunotherapy #Biotechnology